Daring to Fail Forward: The Mindset Catalyzing Healthcare Breakthroughs

The Emerging Biotech Leader
The Emerging Biotech Leader
Daring to Fail Forward: The Mindset Catalyzing Healthcare Breakthroughs
Loading
/

This episode features an interview with Christian Howell, Chief Commercial Officer at Cognito Therapeutics, a biotech company pioneering a neurotechnology approach to treat Alzheimer's disease. Christian draws on his diverse background spanning the military, medical device giant Medtronic, and now the biotech industry.

The conversation covers Cognito's evidence generation strategy to demonstrate the value of their non-invasive neural stimulation therapy. As Christian states, "It's critical to bring all the key players to the table early and be fully transparent about your data - that's how you build trust and alignment around value."

Key takeaways include:

  • The importance of cross-sector partnerships and stakeholder engagement from day one
  • Fostering a culture of innovation through mission-driven leadership
  • Promoting employee accountability to take smart risks
  • Learning quickly from failures versus avoiding them

With experience implementing value-based healthcare models at Medtronic, Christian also shares unique perspectives on driving innovation while developing novel therapies.

Learn from Christian’s approach spanning evidence generation, collaborative value demonstration, and creating an environment primed for breakthrough thinking.  Listen in and get inspired!

Are you leading a biotech and would like to share your experience with our podcast audience? We'd love to hear from you! Please reach out to us.

More Episodes Like This

10-09-2026

From Academia to Biotech: Making the Transition into Biotech Leadership

Mattia Calissano, VP Medical at SSI Strategy, discusses moving from academic research into drug development, communicating scientific evidence to investors, and adapting to the commercial realities of biotech. 
20-08-2026

When the Science Becomes a Company

Samir Ounzain, Scientific Co-Founder and CEO of HAYA Therapeutics, looks at how the founder's role changes as the science becomes a company and the team grows around it. 
08-05-2026

Rethinking Trial Design for Rare Diseases

Marshall Summar, CEO & Founder of Uncommon Cures, discusses why many conventional trial models break down in rare disease settings, and what stronger alternatives look like in practice.

LET’S TALK

You don't have to go it alone! Our experienced team has been there before, and we're ready to guide you through the unknown. Share your challenges with us, and together, we'll create a plan to efficiently reach your milestones and turn your vision into reality.

Building Better Biotechs.